The partners aim to develop a point-of-care diagnostic test using recombinant technology. More specifically, the aim is to develop a test for the detection of antibodies to the malarial parasite using uniquely identified recombinant proteins derivative from the tachyzoite stage of the malarial parasite found in human blood. The diagnostic test format is envisaged to be lateral flow blood test, which will lend itself to low manufacturing costs. Whilst in a European market packaged format the product will be presented through traditional channels, a less sophisticated test presentation will allow the test to be affordable to the primary world areas where the malarial disease is of fundamental economic and health importance. This novel format will require the development of a new test device which will result in a rapid, (less than 5 minutes) accurate, sensitive and specific test which is easy to use and can be developed for further tests.
Funding SchemeEAW - Exploratory awards
79111 Freiburg (In Breisgau)